Commentaries and Select Articles, 2001

Commentaries on recent articles:

The MDR1 C3435T polymorphism: Effects on P-glycoprotein expression/function and clinical significance - Mark J. Dresser

UGT1A1 Polymorphism Predicts Irinotecan Toxicity: Evolving Proof - Sridhar Mani

Genotyping and Drug Response: Use of Single Nucleotide Polymorphisms (SNPs) versus Haplotypes to Predict Albuterol Efficacy - Suzanne Schubbert

Policy for Submission of Commentaries

Select Articles:

Gene variants in disease and therapy:

UGT1A1 Polymorphism
Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60:6921-6926.
[PubMed Abstract]    [CancerResearch FullText]    [Commentary]

Cytochrome P450 isozymes
Kuehl P et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001 Apr;27(4):383-91.
[PubMed Abstract]

Carrier Proteins
Hoffmeyer S et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000 Mar 28;97(7):3473-8.
[PubMed Abstract]    [PubMedCentral FullText]    [Commentary]

Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, Eichelbaum M, Fromm MF. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001 Jun;11(4):293-8.
[PubMed Abstract]    [Commentary]

von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001 Jun;47(6):1048-52.
[PubMed Abstract]   [Commentary]

Clinical applications and drug therapy:

Clinical Applications
Zambon A et al. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 2001 Feb 13;103(6):792-8.
[PubMed Abstract]

Genotyping

Genotyping and Drug Response
Drysdale CM et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. PNAS 2000; 97, 10483-10488.
[PubMed Abstract]    [PubMedCentral FullText]    [Commentary]

Martinez FD et al. Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing. Journal of Clinical Investigation 1997; 100, 3184-3188.
[PubMed Abstract]    [JCI FullText]    [Commentary]